Close-up of microscope in laboratory with flasks visible.
Our Work

Latham & Watkins Advises OmniAb on US$30 Million Private Placement

August 25, 2025
Firm represents the biotechnology company in the transaction.

OmniAb, Inc. (NASDAQ: OABI) has announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of US$1.40 per share (or US$1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately US$30 million, before deducting any placement agent fees and offering-related expenses. The net proceeds from the financing are expected to be used by OmniAb for general corporate purposes. The private placement is expected to close on or about August 26, 2025, subject to customary closing conditions.

Latham & Watkins LLP is advising OmniAb in the transaction with a corporate team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Nadia Patiño and Sterling Swift.

Endnotes